Results from a phase III COVID-19 study showed that oral sabizabulin, a novel dual antiviral and anti-inflammatory agent, improved outcomes in hospitalized moderate-to-severe COVID-19 patients at high risk for acute respiratory distress syndrome and death.
COVID-19 was the third leading cause of death in the United States between March 2020 and October 2021, according to an analysis of national death certificate data by researchers at NCI.
In a survey of nearly 1,200 recent cancer patients and survivors conducted as part of the American Cancer Society Cancer Action Network’s Survivor Views project, more than 80% of respondents said they would be willing to use remote technologies and tools in a trial.
Researchers at Cedars-Sinai Cancer and Johns Hopkins University discovered a novel three-step treatment that disrupts the pancreatic tumor microenvironment in laboratory mice.
Cleveland Clinic researchers measured cellular interactions in a simplified tumor environment consisting of drug-resistant non-small cell lung cancer cells and drug-sensitive precursor cells, aiming to better understand how therapeutic resistance develops.
Results from the pivotal phase II MOUNTAINEER trial showed Tukysa (tucatinib) in combination with trastuzumab was well-tolerated with durable responses in patients with previously treated HER2-positive metastatic colorectal cancer.
FDA accepted the Biologics License Application and granted priority review for mosunetuzumab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, for the treatment of adults with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies.
AstraZeneca will acquire TeneoTwo Inc., including its phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory B-cell non-Hodgkin lymphoma.
The National Cancer Institute approved the following clinical research studies last month.
The House of Representatives on June 22 voted 336-85 to pass legislation that would establish the authorities of the Advanced Research Projects Agency-Health (ARPA-H), President Joe Biden’s proposed high-risk, high-reward biomedical research agency.
